Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Usability and Safety of SB4 Autoinjector and Pre-filled Syringe in RA
NCT03193957Phase 2Completed
- Sponsor
- Samsung Bioepis
- Start
- May 2017
- Primary completion
- Aug 2017
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of etanercept in rheumatoid arthritis (RA), sponsored by Samsung Bioepis. Primary endpoint: Change in Injection site pain score at Week 3. Started May 2017; status: completed.
02
Drugs
etanercept
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT03193957.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03193957.